Search Results for: "Clinic Roundup"
-
Clinic Roundup
AcelRx Pharmaceuticals Inc., of Redwood City, Calif., reported top-line data from a Phase III trial demonstrating that the Sufentanil NanoTab PCA System was noninferior (p < 0.001) to intravenous patient-controlled analgesia with morphine for the primary endpoint of Patient Global Assessment (PGA) of method of pain control over the 48-hour study period as determined by the combined percentage of patients with PGA ratings of "good" or "excellent" (78.5 percent vs. 66.1 percent, respectivelyBioWorld Today | Monday, December 17, 2012 -
Clinic Roundup
Up to 196 patients will be enrolled, and the primary endpoints are reduction in prostate-specific antigen levels and safety...The primary endpoint of the study is immune-related progression-free survival at six monthsBioWorld Today | Friday, December 14, 2012 -
Clinic Roundup
Results showed that dalbavancin achieved its primary endpoint of noninferiority at 48 hours to 72 hours after initiation of therapy, as determined by the cessation of spread of the lesion, as well as the resolution of fever...Durata said the key secondary endpoints were supportive of the primary endpointBioWorld Today | Wednesday, December 12, 2012 -
Clinic Roundup
The study, which will enroll up to 80 subjects and will determine safety as the primary endpoint, is expected to complete in the first half of 2013...The primary endpoint is the change in mean spontaneous pain intensity score between baseline and the last week of 28 days of dosing using the Numeric Pain Rating ScaleBioWorld Today | Tuesday, December 11, 2012 -
Pharma: Clinic Roundup
Iroko Pharmaceuticals LLC, of Philadelphia, reported that a Phase III study of submicron indomethacin for postsurgical pain met its primary endpoint of significant pain relief compared to placeboBioWorld Today | Monday, December 10, 2012 -
Clinic Roundup
As reported previously, Study 202 met its primary endpoint of increased novel dystrophin as assessed in muscle biopsies at week 48 and is now in the long-term extension phase in which patients continue to be followed for safety and clinical outcomesBioWorld Today | Monday, December 10, 2012 -
Pharma: Clinic Roundup
The study enrolled 2,051 subjects at 127 sites in 13 countries, and was designed to evaluate safety and efficacy, with a primary endpoint of mortality or death over two years, and a secondary endpoint of treatment emergent adverse eventsBioWorld Today | Friday, December 7, 2012 -
Clinic Roundup
The primary endpoint of the study is overall survival, and the objective is to demonstrate superiority of elacytarabine over current therapies...The primary endpoints of the study are safety and the change in peak walking time at six months compared to baselineBioWorld Today | Friday, December 7, 2012 -
Clinic Roundup
The primary endpoint is improvement in pain, while secondary or exploratory endpoints will assess improvement in other established fibromyalgia measures and the drug's effect on co-morbidities such as fatigueBioWorld Today | Thursday, December 6, 2012 -
Clinic Roundup
The primary endpoint of the double-blind study was safety and tolerability of the vaccine four weeks after the third injectionBioWorld Today | Tuesday, December 4, 2012 -
Clinic Roundup
The primary endpoint is change in the mean target to background ratio of a radioactive tracer assessed by PET/CT scan after three months of treatmentBioWorld Today | Friday, November 30, 2012 -
Clinic Roundup
Top-line data from the PEARL-SC trial, presented in June, showed the drug missed its primary endpoint, defined as clinical improvement at 24 weeks in the SLE responder index, but further data showed that the BAFF inhibitor produced sustained and greater treatment effects vsBioWorld Today | Thursday, November 29, 2012 -
Clinic Roundup
The study will evaluate the effects of once-daily dosing of AC-1204 for 26 weeks on cognition, pharmacokinetic measures, activities of daily living, resource utilization and quality of life among subjects with mild-to-moderate AD with a primary endpoint tagged to the effects of AC-1204 on memory and cognition as measured by the Alzheimer's Disease Assessment Scale-cognitive subscale after 26 weeks among both carriers and noncarriers of the epsilon 4 variant of the gene apolipoprotein E...It isBioWorld Today | Tuesday, November 27, 2012 -
Pharma: Clinic Roundup
The primary endpoint of the randomized, double-blind, vehicle-controlled study enrolling 1,655 subjects was complete cure rate at week 52BioWorld Today | Tuesday, November 27, 2012 -
Clinic Roundup
The study is expected to enroll 270 patients with histological diagnoses of NASH, and the primary endpoint is to demonstrate the drug's efficacy at one year of treatment vsBioWorld Today | Wednesday, November 21, 2012 -
Clinic Roundup
Data, however, showed the co-primary endpoint of overall survival (OS) failed to reach statistical significance (p = 0.2135BioWorld Today | Tuesday, November 20, 2012 -
Pharma: Clinic Roundup
Pfizer Inc., of New York, said top-line data from a Phase III study testing pregabalin controlled-release (CR) formulation in patients with fibromyalgia indicated that the product had a statistically significant positive effect compared to placebo in the primary endpoint, defined as time to loss of therapeutic response...The first study in partial onset seizures did not meet its primary endpointBioWorld Today | Tuesday, November 20, 2012 -
Pharma: Clinic Roundup
Pfizer Inc., of New York, said top-line results from a Phase III study testing the 165-mg dose and the 330-mg dose of pregabalin controlled-release (CR) formulation in adults with partial onset seizures showed that the trial did not meet its primary endpoint comparing the change in seizure frequency to placebo, although both doses were well toleratedBioWorld Today | Monday, November 19, 2012 -
Clinic Roundup
The primary endpoint of the study was controlling growth or recurrence of the cancer six months after treatment, equivalent to surgery as compared to historical controlsBioWorld Today | Thursday, November 15, 2012 -
Clinic Roundup
The primary endpoint is the Newcastle Paediatric Mitonchondrial Disease Scale, while secondary endpoints will measure effects using neurologic, muscular, imaging and biomarker indices...The study is measuring the feasibility of the injection of NBTXR3 and its activation by radiotherapy in small and big tumors and evaluating the product's safety profile as the primary endpointsBioWorld Today | Wednesday, November 14, 2012
Category
BioWorld | 3525 Piedmont Road
Building 6, Suite 400 | Atlanta, Georgia 30305, USA
Building 6, Suite 400 | Atlanta, Georgia 30305, USA
Part of Thompson Media Group LLC
Free Ezine
Sign up for Perspectives FREE e-mail newsletter.
Customer Service: In the U.S. and Canada: 1-800-477-6307
Outside the U.S.: 1-404-262-5476
customerservice@bioworld.com
Hours: Monday - Thursday, 8:30 am - 6:00 pm EST
Friday, 8:30am - 4:30 pm EST
Outside the U.S.: 1-404-262-5476
customerservice@bioworld.com
Hours: Monday - Thursday, 8:30 am - 6:00 pm EST
Friday, 8:30am - 4:30 pm EST
Copyright @ 2013 AHC Media. Reproduction, reposting content is strictly prohibited.